ALLMedicine™ Growth Hormone Deficiency Center

Jan 21st, 2023 - The evidence of long-term polyethylene glycol recombinant human growth hormone (PEG-rhGH) in pediatric growth hormone deficiency (GHD) is limited. This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD ...

Jan 18th, 2023 - Background: Recombinant human growth hormone (GH) is used in the treatment of short stature due to growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age with failure of catch up growth, chronic renal failure ...

Jan 12th, 2023 - A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females)...

Dec 30th, 2022 - Gene mutations encoding transcription factors, including SOX2, have been associated with growth hormone deficiency (GHD) and abnormal pituitary development. Guidelines on GHD management in the transition period state that patients with genetic-bas...

Dec 28th, 2022 - Hypopituitarism refers to insufficiency of one or more hormones of the pituitary and can be due to myriad causes. The clinical and radiological spectrum of the condition is heterogeneous, based on the age, gender, clinical setting and/or other pas...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Jan 18th, 2023 - Background: Recombinant human growth hormone (GH) is used in the treatment of short stature due to growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age with failure of catch up growth, chronic renal failure ...

Jan 12th, 2023 - A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females)...

Dec 23rd, 2022 - This multicenter, randomized, open-labeled, positive controlled study is divided into two stages. The first one is aimed to exploit the optimal dose of Y-shape pegylated somatropin, while the second one is aimed to confirm the efficacy and safety ...

Dec 21st, 2022 - Annually, over 250,000 Canadians and over 40 million individuals worldwide will suffer an uncomplicated concussion (head injury with no intracranial abnormalities seen on imaging). Most individuals will recover within weeks of injury but over 30% ...

Dec 20th, 2022 - Children often present to pediatricians and pediatric endocrinologists because of abnormal body growth, including both childhood growth failure and, less commonly, overgrowth. Sometimes the cause is evident, for example, growth hormone deficiency ...

Nov 22nd, 2022 - The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin glargine-aglr (Rezvoglar), for pediatric and adult patients with diabetes, the agency announced. Patients with diabetes and chronic kidney disease should b...

Mar 23rd, 2022 - In a study of 7,422 nursing home residents with type 2 diabetes, 17% met criteria for glycemic overtreatment and another 23% met criteria for potential overtreatment. (Journal of the American Geriatrics Society) Aeterna Zentaris announced some del...

Feb 20th, 2022 - Interim data from a long-term extension study of setmelanotide (Imcivree) for pediatric and adult patients with Bardet-Biedl Syndrome found an average BMI reduction of 14.3% from baseline and a 14.9% drop in body weight, Rhythm Pharmaceuticals ann...

Jan 24th, 2022 - Note that some links may require registration or subscription. Strained hospitals are calling potentially infectious healthcare workers back to their posts, citing the CDC's latest guidance. (Washington Post) NIAID Director Anthony Fauci, MD, said...

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...